Celltrion Files Phase 3 Clinical Trial Plan for CT-P13 SC in US for Rheumatoid Arthritis Aiming to Expand Indications
On July 24, 2026, Celltrion submitted a global Phase 3 clinical trial plan to the US FDA for CT-P13 SC in patients with moderate to severe active rheumatoid arthritis.
The trial is a randomized, placebo-controlled, double-blind, parallel-group design involving 296 patients over a 52-week treatment period to evaluate efficacy and safety.
CT-P13 SC is a subcutaneous formulation of the infliximab biosimilar Remsima IV, already approved for ulcerative colitis and Crohn's disease. This trial aims to expand the indication to rheumatoid arthritis, offering more treatment opportunities.
However, the probability of a clinical trial drug ultimately receiving final approval is statistically around 10%, and investors should consider this uncertainty.
[AI Summary]This disclosure represents the submission of a clinical trial plan for label expansion of an existing approved product, which does not involve capital raising or direct shareholder return. While successful expansion could enhance revenue and shareholder value, the inherent clinical risk and long-term uncertainty lead to a neutral assessment of stock price impact.
KOSPI Filing Information
Investment Judgment Related Major Management Matters (CTP13 SC (Zimpentra) US Phase 3 Clinical Trial Plan Application (Rheumatoid Arthritis Patients))